MAXCYTE, INC.

Regulatory Filings • Oct 27, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5694N

MaxCyte, Inc.

27 October 2016

MaxCyte, Inc.

("MaxCyte" or the "Company")

Result of Annual General Meeting

Maryland, USA - 27 October 2016: MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that at its Annual General Meeting held yesterday at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA, all resolutions were duly passed.

- ENDS -

For further information please contact:

MaxCyte	+1 301 944 1660
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking)	+44 (0) 20 7886 2500
Financial PR Advisor Consilium Strategic Communications	+44 (0)203 709 5700 [email protected]
Mary-Jane Elliott Chris Welsh Lindsey Neville

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/ 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLQLLLQBFLFBV